Effects of policosanol on older patients with hypertension and type II hypercholesterolaemia

Drugs in R and D

Volumn 3, Issue 3, 2002, Pages 159-172

  Castaño, Gladys ^a   Más, Rosa ^b   Fernández, Julio C ^b   Fernández, Lilia ^b   Illnait, José ^a   López, Ernesto ^a  

^a Surgical Medical Research Center   (Cuba)

^b Center of Natural Products   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANXIOLYTIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CHOLESTEROL; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; NICOTINIC ACID DERIVATIVE; NITRATE; ORAL ANTIDIABETIC AGENT; PLACEBO; POLICOSANOL; FATTY ALCOHOL;

ABDOMINAL PAIN; ADULT; AGED; ARTHRALGIA; ARTICLE; CAUSE OF DEATH; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; FEMALE; HEADACHE; HEART ARREST; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; INSOMNIA; ISCHEMIC HEART DISEASE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NAUSEA; NERVOUSNESS; PARALLEL DESIGN; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; STATISTICAL ANALYSIS; STOMACH PH; THORAX PAIN; ULCER; UNSTABLE ANGINA PECTORIS; VASCULAR DISEASE; VERTIGO; BLOOD; CHI SQUARE DISTRIBUTION; COMPARATIVE STUDY; HYPERLIPOPROTEINEMIA TYPE 2; MIDDLE AGED;

AGED; AGED, 80 AND OVER; CHI-SQUARE DISTRIBUTION; DOUBLE-BLIND METHOD; FATTY ALCOHOLS; FEMALE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; HYPERTENSION; LIPIDS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 0036043705     PISSN: 11745886     EISSN: None     Source Type: Journal    
DOI: 10.2165/00126839-200203030-00004     Document Type: Article

References (76)

1. World Health Organization. World Health Report 1998: life in the 21st century - a vision of all Geneva. Switzerland: World Health Organization, 1998
2. Anderson KM, Wilson PWF, Odell PM, et al. An updated risk profile: a statement of health professionals. Circulation 1991; 83: 356-62
3. Zanchetti A. Hyperlipidemia in the hypertensive patient. Am J Med 1994; 96 Suppl A: 6A-3S
4. Stamler J, Wentworth D, Neaton JD. Prevalence and prognostic significance of hypercholesterolemia in men with hypertension. JAMA 1986; 80 Suppl 2A: 33-6
5. Laurenzi M, Mancini M, Menotti A, et al., on behalf of the Gubbio Study Group. Multiple risk factors in hypertension: results from the Gubbio study. J Hypertens 1990; 8 Suppl. 201: S7-S12
6. Guidelines Subcommittee. 1993 Guidelines for the management of mild hypertension: memorandum for a World Health Organization/International Society of Hypertension meeting. J Hypertens 1993; 11: 905-18
7. Pyörala K, De Backer G, Graham I, et al., on behalf of the Task Force. Prevention of coronary heart disease in clinical practice: recommendations of the Task force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J 1994; 15: 1300-1331/
8. Expert Panel of Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97
9. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4 444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9
10. Sacks FM, Pfeffer MA, Moyé LA, et al., for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-9
11. Tonkin A, Aylward P, Colqhoun D, et al.: Prevention of cardiovascular events and deaths with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. New Engl J Med 1998; 339: 1349-57
12. Shepherd S, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-7
13. Weis S, Clearfield M, Downs JR, Gotto A. The Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/ TexCAPS). Primary prevention of acute major coronary events in women and men with average cholesterol in cholesterol-lowering therapy. In: Grundy S, editor. Evaluation of clinical trial evidence. New York: Marcel Dekker Inc, 2000: 151-172
14. Burt VL, Whelton P, Roccella EJ, et al.: Prevalence of hypertension in the US adult population: results from the Third National Health and Nutrition examination Survey 1988-1991. Hypertension 1995; 25: 305-13
15. Manolio TA, Pearson TA, Wenger NK, et al. Cholesterol and heart disease in older persons and women: review of an NHLBI workshop. Ann Epidemiol 1992; 2: 161-76
16. Capurso A. Lipid metabolism and cardiovascular risk: should hypercholesterolemia be treated in the elderly? J Hypertens 1992; 10: 565-8
17. Gotto AM, Assman G, Carmena R, et al. The ILIB lipid handbook for clinical practice: blood lipids and coronary heart disease. 2nd ed. New York: International Lipid Information Bureau (ILIB), 2000
18. Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413-46
19. Whelton PK. Epidemiology of hypertension. Lancet 1994; 344: 101-6
20. MacMahon S, Peto R, Cutler J, et al. : Blood pressure, stroke and coronary heart disease I: prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765-74
21. Kannel WB. Elevated systolic blood pressure as a cardiovascular risk factor. Am J Cardiol 2000; 85: 251-5
22. Black HR. The paradigm has shifted to systolic blood pressure. Hypertension 1999; 34: 386-7
23. Psaty BM, Furberg CD, Kuller LH, et al. : The association between blood pressure level and the risk of myocardial infarction, stroke and total mortality. The Cardiovascular Health Study. Arch Intern Med 2001; 161: 1183-92
24. Kaplan NM. What is the goal blood pressure for the treatment of hypertension?. Arch Intern Med 2001 161: 1480-1482
25. Moser M. Is it time for a new approach to the initial treatment of hypertension? Arch Intern Med 2001; 161: 1140-4
26. Lawrence J, Appel MPH, Espeland MA, et al. : Effects of reduced sodium intake on hypertension control in older individuals: results from the trial of nonpharmacologic intervention in the elderly (TONE). Arch Intern Med 2001; 161: 685-93
27. Anonymous. Drug treatment of hypertension in the elderly. Drugs: Ther & Perspect 1993; 1: 7-12
28. Hernández F, Illnait J, Más R, et al. : Effects of policosanol on serum lipids and lipoproteins in healthy volunteers. Curr Ther Res 1992; 51: 568-75
29. Pons P, Jiménez A, Rodríguez M, et al. : Effects of policosanol in elderly hypercholesterolemic patients. Curr Ther Res 1993; 53: 265-9
30. Castaño G, Canetti M, Morera M, et al. : Efficacy and tolerability of policosanol in elderly patients with type II hypercholesterolemia: a 12 months study. Curr Ther Res 1993; 56: 819-28
31. Pons P, Rodríguez M, Robaina C, et al. Effects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolemia and tolerability to treatment. Int J Clin Pharmacol Res 1994; XIV: 27-33
32. Aneiros E, Más R, Calderón B, et al. : Effect of policosanol in lowering-cholesterol levels in patients with type II hypercholesterolemia. Curr Ther Res 1995; 56: 176-82
33. Canetti M, Morera M, Illnait J, et al. One year study on the effect of policosanol (5mg-twice-a-day) on lipid profile in patients with type II hypercholesterolemia. Adv Ther 1995; 12: 245-54
34. Castaño G, Tula L, Canetti M, et al. Effects of policosanol in hypertensive patients with type II Hypercholesterolemia. Curr Ther Res 1996; 57: 691-9
35. Zardoya R, Tula L, Castaño G, et al. Effects of policosanol on hypercholesterolemic patients with disturbances on serum biochemical indicators of hepatic function. Curr Ther Res 1996; 57: 568-77
36. Ortensi G, Gladstein H, Valli H, et al. A comparative study of policosanol vs simvastatin in elderly patients with hypercholesterolemia. Curr Ther Res 1997; 58: 390-401
37. Canetti M, Morera MS, Más R, et al. Effects of policosanol on primary hypercholesterolemia: a 3 years open follow-up. Curr Ther Res 1997: 58: 868-75
38. Más R, Castaño G, Illnait J, et al. Effects of policosanol on patients with type II hypercholesterolemia and additional coronary risk factors. Clin Pharmacol Ther 1998; 65: 439-47
39. Castaño G, Más R, Fernández JC, et al. A long-term open study of the efficacy and tolerability of policosanol in patients with high global coronary risk. Curr Ther Res 1999; 60: 379-91
40. Castaño G, Más R, Arruzazabala ML, et al. Effects of policosanol, pravastatin on lipid profile, platelet aggregation, endothelemia in older hypercholesterolemic patients. Int J Clin Pharmacol Res 1999; XIX: 105-16
41. Castaño G, Más R, Fernández JC, et al. Effects of policosanol in older patients with type II hypercholesterolemia and high coronary risk. J Gerontol Med Sci 2001; 56: M186-92
42. Torres O, Agramonte AJ, Illnait J, et al. Treatment of hypercholesterolemia in NIDDM with policosanol. Diabetes Care 1995; 18: 393-7
43. Crespo N, Alvarez R, Más R, et al. Effect of policosanol on patients with non-insulin-dependent diabetes mellitus and hypercholesterolemia: a pilot study. Curr Ther Res 1997; 58: 44-51
44. Crespo N, Illnait J, Mas R, et al. Comparative study of the efficacy and tolerability of policosanol and lovastatin in patients with hypercholesterolemia and non insulin dependent diabetes mellitus. Int J Clin Pharmacol Res 1999; XIX: 105-16
45. Menéndez R, Fernández I, Del Río A, et al. Policosanol inhibits cholesterol biosynthesis and enhances LDL processing in cultured human fibroblasts. Biol Res 1994; 27: 199-203
46. Menéndez R, Arruzazabala ML, Más R, et al. : Cholesterol-lowering effect of policosanol on rabbits with hypercholesterolemia induced by a wheat starch-casein diet. Br J Nutr 1996; 77: 923-32
47. Alemán C, Más R, Hernández C, et al. A 12 months study of policosanol oral toxicity in Sprague-Dawley rats. Toxicol Lett 1994; 70: 77-87
48. Mesa AR, Más R, Noa M, et al. Toxicity of policosanol in Beagle dogs: one year study. Toxicol Lett 1994; 73: 81-90
49. Rodríguez MD, García H. Teratogenic and reproductive studies of policosanol in the rat and rabbit. Teratog Carcinog Mutagen 1994; 14: 107-13
50. Alemán CL, Más R, Noa M, et al. Carcinogenicity of policosanol in Sprague Dawley rats: A 24 months study. Teratog Carcinog Mutagen 1994; 14: 239-49
51. Alemán C, Noa M, Cerejido E, et al. Carcinogenicity of policosanol in mice: a 18 months study. Fd Chem Toxicol 1995; 33: 573-8
52. Rodríguez MD, Sánchez M, García H. Multigeneration reproduction study of policosanol in rats. Toxicol Lett 1997; 90: 97-106
53. Rodríguez MD, García H. Evaluation of peri- and post-natal toxicity of policosanol in rats. Teratog Carcinog Mutagen 1998; 18: 1-7
54. Castaño G, Más R, Roca J, et al. A double-blind, placebo-controlled study of the effects of policosanol in patients with intermittent claudication. Angiology 1998; 50: 123-30
55. Castaño G, Mas R, Fernández L, et al. A long-term study of policosanol in the treatment of Intermittent Claudication. Angiology 2001; 52: 115-25
56. Más R, Rivas P, Izquierdo JE, et al. Pharmacoepidemiologic study of policosanol. Curr Ther Res 1999; 60: 458-67
57. Seigler L, Wu WT. Separation of serum high-density lipoprotein for cholesterol determination: ultracentrifugation vs precipitation with sodium phosphotungstate and magnesium chloride. Clin Chem 1981; 27: 838-41
58. Friedewald WT, Levy RI, Friederickson SD. Estimation of the concentration of low-density-lipoprotein cholesterol in plasma without of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502
59. Schectman G, Hiatt J. Drug therapy for hypercholesterolemia in patients with cardiovascular disease: factors limiting achievement of lipid goals. Am J Med 1996; 100: 197-204
60. Leslie SJ, Smith DG, Campbell LM, et al. Treating to LDL-C target: resource utilization with atorvastatin compared with fluvastatin, pravastatin and simvastatin in patients with CHD. Abstracts of the 13th International Symposium on Drugs Affecting Lipid Metabolism; 1998 May 30-June 3; Florence,
61. Wood D, De Backer G, Faergerman O, et al. Prevention of coronary heart disease in clinical practice. Eur Heart J 1998; 19: 1434-503
62. Muls E, De Backer G, De Bacquer D, et al. LIPI-WATCH, a Belgian/Luxembourg survey on achievement of European atherosclerosis society lipid goals. Clin Drug Invest 2000; 19: 219-29
63. Wood D, De Backer G, Faergeman O. et al: Prevention of coronary heart disease in clinical practice. Eur Heart J 1998, 19: 1434-1503.
64. Santanello NC, Barber BL, Applegate WB, et al. Effect of pharmacologic lipid lowering on health-related quality of life in older persons: results from the cholesterol reduction in seniors program (CRISP) pilot study. J Am Geriatr Soc 1997; 4S: 8-14
65. Arruzazabala ML, Carbajal D, Más R, et al. Effects of policosanol on platelet aggregation in rats. Thromb Res 1992; 69: 321-7
66. Arruzazabala ML, Carbajal D, Molina V, et al. : Estudio farmacológico de la interacción entre el policosanol y la aspirina en animales de experimentación. Rev Iberoam Tromb Hemost 1992; 5: 17-20
67. Arruzazabala ML, Carbajal D, Molina V, et al. Effect of policosanol on cerebral ischemia in mongolian gerbils: role of prostacyclin and thromboxane A2. Prostaglandins Leukot Essent Fatty Acids 1993; 49: 695-7
68. Arruzazabala ML, Valdés S, Más R, et al. Effect of policosanol successive dose increases on platelet aggregation in healthy volunteers. Pharmacol Res 1996; 34: 181-5
69. Carbajal D, Arruzazabala ML, Valdés S, et al. Effect of policosanol on platelet aggregation and serum levels of arachidonic acid metabolites in healthy volunteers. Prostaglandins Leukot Essent Fatty Acids 1998; 58: 61-4
70. Arruzazabala ML, Más R, Molina V, et al. : Effect of policosanol on platelet aggregation in type II hypercholesterolemic patients. Int J Tissue React 1998; XX: 119-24
71. Menéndez R, Fraga V, Amor AM, et al. Oral administration of policosanol inhibits in vitro copper ion-induced rat lipoprotein peroxidation. Physiol Behav 1999; 67: 1-7
72. Menéndez R, Más R, Amor AM, et al. Effects of policosanol treatment on the susceptibility of low density lipoprotein (LDL) isolated from healthy volunteers to oxidative modification in vitro. Br J Clin Pharmacol 2000; 50: 225-62
73. Menéndez R, Más R, Amor A, et al. Effects of policosanol on the low density lipoprotein (LDL) isolated on hypercholesterolemic patients at high coronary risk to in vitro copper-mediated lipid peroxidation. Curr Ther Res 2000; 61: 609-20
74. Sposito AC, Mansur AP, Coelho OR, et al. Additional reduction in blood pressure after cholesterol-lowering treatment with statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril). Am J Cardiol 1999; 83: 1497-9
75. Laufs U, La Fata V, Plutzky J, et al. Upregulation of endothelial nitric oxide by HMGCoA reductase inhibitors. Circulation 1998; 97: 1129-35
76. Molina V, Arruzazabala ML, Carbajal D, et al. Effect of policosanol on arterial blood pressure in rats: study of the pharmacological interaction with nifedipine and propranolol. Arch Med Res 1998; 29: 21-4